Immunohistochemical Expression of CXCL5 as a Valuable Prognostic Marker in Urinary Bladder Urothelial Carcinoma
试验速览
- 阶段
- 不适用
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- assess the expression of CXCL5 in urothelial carcinoma
研究概览
简要总结
Urothelial carcinoma is common malignant tumor worldwide, it remains a challenge in the oncology field, it is an ideal for research on biomarkers that could identify tumor progression and prognosis. CXCL5 have been implicated in progression of many cancers, but their significance in urinary bladder UC remains unclear.
详细描述
Bladder carcinoma has become a common cancer globally, Incidence rates are highest in Europe, the United States and Egypt. In Egypt, bladder carcinoma was considered the third most common tumor; Egyptian males have the highest mortality rates. UC of the urinary bladder represents about 90% of all bladder cancers.
CXCL5 is a chemokine, belonging to ‗ELR+' subgroup. It plays an important role in angiogenesis and tumor migration. Numerous reports have indicated that CXCL5 plays important roles in cancer progression, including cholangiocarcinoma, prostate cancer, and gastric cancer. Studying the IHC expression of CXCL5 in UC to assess its role in tumor cell proliferation, migration and spread is needed.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with primary invasive and non-invasive urinary bladder urothelial carcinomas.
排除标准
- •- Patients received pre-operative chemotherapy or radiotherapy.
- •Patients with insufficient clinical data.
- •Specimens with extensive necrosis
- •Tiny specimens which are insufficient for accurate diagnosis.
结局指标
主要结局
assess the expression of CXCL5 in urothelial carcinoma
时间窗: 1 month
Immunohistochemical study
次要结局
未报告次要终点
研究者
Nagwa Abd El-Sadek Ahmed
Lecturer at Pathology Department, Faculty of Medicine, Sohag University
Sohag University